Trade Curis, Inc. - CRIS CFD

Add to favourite

14.6884

4.67%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.7332

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Curis Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	15.4084
Open*	15.8384
1-Year Change*	1524.28%
Day's Range*	14.6484 - 15.8684
52 wk Range	3.80-20.00
Average Volume (10 days)	35.55K
Average Volume (3 months)	1.90M
Market Cap	72.14M
P/E Ratio	-100.00K
Shares Outstanding	5.89M
Revenue	10.21M
EPS	-9.35
Dividend (Yield %)	N/A
Beta	3.80
Next Earnings Date	Mar 11, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	14.6884	-1.1500	-7.26%	15.8384	15.8684	14.5484
Apr 17, 2024	15.4084	0.1700	1.12%	15.2384	15.9884	15.2384
Apr 16, 2024	14.7584	0.5100	3.58%	14.2484	14.9984	14.0984
Apr 15, 2024	13.9384	-0.7700	-5.24%	14.7084	14.7184	13.8584
Apr 12, 2024	14.7784	-0.6900	-4.46%	15.4684	15.4684	14.6984
Apr 11, 2024	15.6084	0.6100	4.07%	14.9984	15.7884	14.7884
Apr 10, 2024	15.1984	0.2600	1.74%	14.9384	15.1984	14.9384
Apr 9, 2024	15.0784	-0.9700	-6.04%	16.0484	16.1084	14.6084
Apr 8, 2024	16.0184	-0.2100	-1.29%	16.2284	16.4684	15.7584
Apr 5, 2024	16.3484	0.5700	3.61%	15.7784	16.6384	14.8784
Apr 4, 2024	15.7084	2.3000	17.15%	13.4084	16.9384	13.4084
Apr 3, 2024	12.8984	0.8800	7.32%	12.0184	12.9984	11.9884
Apr 2, 2024	11.9184	-0.2200	-1.81%	12.1384	12.1584	11.6084
Apr 1, 2024	12.2784	1.9000	18.31%	10.3784	12.3884	10.3784
Mar 28, 2024	10.5784	0.4200	4.13%	10.1584	10.7784	10.1584
Mar 27, 2024	10.4984	0.4900	4.90%	10.0084	10.7284	9.9084
Mar 26, 2024	9.9784	-0.4900	-4.68%	10.4684	10.5084	9.8984
Mar 25, 2024	10.4884	-0.0100	-0.10%	10.4984	10.7284	10.4684
Mar 22, 2024	10.4084	-0.1500	-1.42%	10.5584	10.8384	10.3584
Mar 21, 2024	10.7584	0.5500	5.39%	10.2084	10.7984	10.2084

Curis, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Curis Inc Earnings Release Q1 2024 Curis Inc Earnings Release Forecast - Previous -
Tuesday, May 21, 2024
Time (UTC) 14:00	Country US	Event Curis Inc Annual Shareholders Meeting Curis Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, May 22, 2024
Time (UTC) 14:00	Country US	Event Curis Inc Annual Shareholders Meeting Curis Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Curis Inc Earnings Release Q2 2024 Curis Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	10.162	10.649	10.835	10.004	10.428
Revenue	10.162	10.649	10.835	10.004	10.428
Cost of Revenue, Total	0.257	0.533	0.534	0.503	0.563
Gross Profit	9.905	10.116	10.301	9.501	9.865
Total Operating Expense	63.182	51.814	35.733	37.855	39.761
Selling/General/Admin. Expenses, Total	19.648	17.297	12.131	11.555	14.785
Research & Development	43.277	34.884	23.068	22.302	24.413
Operating Income	-53.02	-41.165	-24.898	-27.851	-29.333
Interest Income (Expense), Net Non-Operating	1.119	0.211	0.063	-0.177	-3.242
Other, Net	-4.771	-4.482	-5.073	-4.113	0
Net Income Before Taxes	-56.672	-45.436	-29.908	-32.141	-32.575
Net Income After Taxes	-56.672	-45.436	-29.908	-32.141	-32.575
Net Income Before Extra. Items	-56.672	-45.436	-29.908	-32.141	-32.575
Net Income	-56.672	-45.436	-29.908	-32.141	-32.575
Income Available to Common Excl. Extra. Items	-56.672	-45.436	-29.908	-32.141	-32.575
Income Available to Common Incl. Extra. Items	-56.672	-45.436	-29.908	-32.141	-32.575
Diluted Net Income	-56.672	-45.436	-29.908	-32.141	-32.575
Diluted Weighted Average Shares	4.66963	4.57846	2.43352	1.65903	1.65592
Diluted EPS Excluding Extraordinary Items	-12.1363	-9.92387	-12.29	-19.3734	-19.6719
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	-12.1363	-10.1204	-12.29	-17.2668	-19.6719
Total Extraordinary Items
Unusual Expense (Income)		-0.9	0	3.495

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	2.197	2.297	2.887	2.825	2.393
Revenue	2.197	2.297	2.887	2.825	2.393
Cost of Revenue, Total	0.074	0.024	0.071	0.062	0.042
Gross Profit	2.123	2.273	2.816	2.763	2.351
Total Operating Expense	14.335	13.924	13.107	15.431	17.454
Selling/General/Admin. Expenses, Total	4.249	4.76	4.33	4.556	5.089
Research & Development	10.012	9.14	8.706	10.813	12.323
Operating Income	-12.138	-11.627	-10.22	-12.606	-15.061
Interest Income (Expense), Net Non-Operating	0.815	0.652	0.542	0.335	0.162
Other, Net	-0.638	-0.584	-1.651	-1.023	-1.041
Net Income Before Taxes	-11.961	-11.559	-11.329	-13.294	-15.94
Net Income After Taxes	-11.961	-11.559	-11.329	-13.294	-15.94
Net Income Before Extra. Items	-11.961	-11.559	-11.329	-13.294	-15.94
Net Income	-11.961	-11.559	-11.329	-13.294	-15.94
Income Available to Common Excl. Extra. Items	-11.961	-11.559	-11.329	-13.294	-15.94
Income Available to Common Incl. Extra. Items	-11.961	-11.559	-11.329	-13.294	-15.94
Diluted Net Income	-11.961	-11.559	-11.329	-13.294	-15.94
Diluted Weighted Average Shares	4.8343	4.83068	4.82295	4.68956	4.58255
Diluted EPS Excluding Extraordinary Items	-2.4742	-2.39283	-2.34898	-2.83481	-3.47841
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-2.4742	-2.39283	-2.34898	-2.83481	-3.47841
Unusual Expense (Income)

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	92.119	122.375	172.752	25.003	27.961
Cash and Short Term Investments	85.623	115.884	168.494	20.543	24.27
Cash & Equivalents	19.658	40.014	129.61	15.43	23.636
Short Term Investments	65.965	75.87	38.884	5.113	0.634
Total Receivables, Net	2.975	3.224	3.043	3.244	2.864
Accounts Receivable - Trade, Net	2.975	3.224	3.043	3.244	2.864
Prepaid Expenses	3.521	3.267	1.215	1.063	0.827
Total Assets	108.848	162.301	204.358	35.107	37.365
Property/Plant/Equipment, Total - Net	5.09	6.254	7.241	0.303	0.267
Property/Plant/Equipment, Total - Gross	7.547	8.479	9.307	2.39	2.292
Accumulated Depreciation, Total	-2.457	-2.225	-2.066	-2.087	-2.025
Goodwill, Net	8.982	8.982	8.982	8.982	8.982
Other Long Term Assets, Total	2.657	0.726	0.819	0.819	0.155
Total Current Liabilities	10.013	13.438	10.079	6.541	13.25
Accounts Payable	3.193	6.417	4.166	4.465	2.909
Accrued Expenses	6.82	7.021	5.356	2.076	3.457
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases		0	0.557	0	6.884
Total Liabilities	62.296	71.594	73.688	69.018	41.861
Total Long Term Debt	0	0	0.334	0	28.6
Long Term Debt		0	0.334	0	28.6
Other Liabilities, Total	52.283	58.156	63.275	62.477	0.011
Total Equity	46.552	90.707	130.67	-33.911	-4.496
Common Stock	0.966	0.916	0.915	0.332	0.332
Additional Paid-In Capital	1194.77	1182.22	1176.65	982.738	980.012
Retained Earnings (Accumulated Deficit)	-1149	-1092.32	-1046.89	-1016.98	-984.84
Treasury Stock - Common					0
Other Equity, Total	-0.186	-0.109	-0.003		0
Total Liabilities & Shareholders’ Equity	108.848	162.301	204.358	35.107	37.365
Total Common Shares Outstanding	4.83038	4.58227	4.57512	1.66209	1.65796
Other Current Assets, Total			0	0.153
Long Term Investments	0	23.964	14.564

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	73.426	67.851	78.01	92.119	105.717
Cash and Short Term Investments	68.498	63.487	71.759	85.623	98.689
Cash & Equivalents	24.468	19.822	31.696	19.658	29.851
Short Term Investments	44.03	43.665	40.063	65.965	68.838
Total Receivables, Net	2.848	2.386	2.314	2.975	2.886
Accounts Receivable - Trade, Net	2.848	2.386	2.314	2.975	2.886
Prepaid Expenses	2.08	1.978	3.937	3.521	4.142
Total Assets	89.975	84.308	94.544	108.848	122.854
Property/Plant/Equipment, Total - Net	3.899	4.301	4.701	5.09	5.498
Goodwill, Net	8.982	8.982	8.982	8.982	8.982
Long Term Investments				0	0
Other Long Term Assets, Total	3.668	3.174	2.851	2.657	2.657
Total Current Liabilities	13.708	9.682	8.069	10.013	13.742
Accounts Payable	5.221	2.686	2.642	3.193	5.756
Accrued Expenses	8.487	6.996	5.427	6.82	7.986
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases
Total Liabilities	60.384	58.084	57.954	62.296	67.109
Total Long Term Debt	0	0	0	0	0
Long Term Debt
Other Liabilities, Total	46.676	48.402	49.885	52.283	53.367
Total Equity	29.591	26.224	36.59	46.552	55.745
Common Stock	0.059	0.993	0.966	0.966	0.964
Additional Paid-In Capital	1214.13	1197.75	1196.17	1194.77	1192.93
Retained Earnings (Accumulated Deficit)	-1184.7	-1172.52	-1160.56	-1149	-1137.67
Other Equity, Total	0.103	0.002	0.009	-0.186	-0.479
Total Liabilities & Shareholders’ Equity	89.975	84.308	94.544	108.848	122.854
Total Common Shares Outstanding	5.88531	4.96724	4.83089	4.83038	4.81992
Property/Plant/Equipment, Total - Gross				7.547
Accumulated Depreciation, Total				-2.457

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-56.672	-45.436	-29.908	-32.141	-32.575
Cash From Operating Activities	-54.337	-37.619	-25.739	-26.205	-30.065
Cash From Operating Activities	0.233	0.158	0.144	0.125	0.177
Non-Cash Items	8.92	6.655	2.977	7.369	3.835
Cash Interest Paid	4.112	4.437	5.05	4.716	3.919
Changes in Working Capital	-6.818	1.004	1.048	-1.558	-1.502
Cash From Investing Activities	33.023	-47.895	-49.048	-4.456	21.374
Capital Expenditures	-0.416	0	-0.677	-0.041	-0.085
Other Investing Cash Flow Items, Total	33.439	-47.895	-48.371	-4.415	21.459
Cash From Financing Activities	0.867	-4.172	188.814	23.271	-5.961
Issuance (Retirement) of Stock, Net	5.842	0.3	176.507	0.068	0.143
Issuance (Retirement) of Debt, Net		0	0.891	-38.987	-6.104
Net Change in Cash	-20.447	-89.686	114.027	-7.39	-14.652
Financing Cash Flow Items	-4.975	-4.472	11.416	62.19	0

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-11.559	-56.672	-45.343	-32.049	-16.109
Cash From Operating Activities	-12.199	-54.337	-42.069	-28.947	-16.815
Cash From Operating Activities	0.064	0.233	0.141	0.08	0.036
Non-Cash Items	1.497	8.92	6.527	4.794	2.319
Cash Interest Paid	0.661	4.112	3.093	2.091	1.074
Changes in Working Capital	-2.201	-6.818	-3.394	-1.772	-3.061
Cash From Investing Activities	26.243	33.023	29.56	25.257	-3.083
Capital Expenditures	0	-0.416	-0.416	-0.364	-0.011
Other Investing Cash Flow Items, Total	26.243	33.439	29.976	25.621	-3.072
Cash From Financing Activities	-2.006	0.867	2.255	-2.407	-1.648
Financing Cash Flow Items	-2.013	-4.975	-3.557	-2.556	-1.648
Issuance (Retirement) of Stock, Net	0.007	5.842	5.812	0.149	0
Net Change in Cash	12.038	-20.447	-10.254	-6.097	-21.546
Issuance (Retirement) of Debt, Net

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Curis, Inc. Company profile

About Curis, Inc.

Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).

Equity composition

Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.

Industry:

Biotechnology & Medical Research (NEC)

128 Spring Street
4 Maguire Road
LEXINGTON
MASSACHUSETTS 02421
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024